Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00EPS
|
||||
| Former ID |
DIB018047
|
||||
| Drug Name |
compound 4
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Myocardial ischemia; Reperfusion injury [ICD9: 459.89; ICD10:I99.8] | Clinical trial | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H27N5O6S
|
||||
| InChI |
InChI=1S/C21H27N5O6S/c22-19(23)16-8-6-14(7-9-16)10-24-20(29)17(11-27)25-21(30)18(12-28)26-33(31,32)13-15-4-2-1-3-5-15/h1-9,17-18,26-28H,10-13H2,(H3,22,23)(H,24,29)(H,25,30)/t17-,18+/m0/s1
|
||||
| InChIKey |
ZNOKJHWJKULOGM-ZWKOTPCHSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Urokinase-type plasminogen activator | Target Info | Inhibitor | [1] | |
| KEGG Pathway | NF-kappa B signaling pathway | ||||
| Complement and coagulation cascades | |||||
| Transcriptional misregulation in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| PANTHER Pathway | Blood coagulation | ||||
| Plasminogen activating cascade | |||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| E2F transcription factor network | |||||
| Beta3 integrin cell surface interactions | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| Beta2 integrin cell surface interactions | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| FGF signaling pathway | |||||
| Reactome | Dissolution of Fibrin Clot | ||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| Senescence and Autophagy in Cancer | |||||
| Complement and Coagulation Cascades | |||||
| Endochondral Ossification | |||||
| Wnt Signaling Pathway | |||||
| Wnt Signaling Pathway and Pluripotency | |||||
| Blood Clotting Cascade | |||||
| Dissolution of Fibrin Clot | |||||
| Osteopontin Signaling | |||||
| References | |||||
| REF 1 | Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6545). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.